Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Helius Medical Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)--SOLANA COMPANY (NASDAQ:HSDT) (HSDT OR THE COMPANY), FORMERLY KNOWN AS HELIUS MEDICAL TECHNOLOGIES, INC., TODAY ANNOUNCED IT HAS SELECTED BITGO, THE DIGITAL ASSET INFRASTRUCTURE COMPANY, TO SERVE AS A CUSTODIAN FOR THE COMPANY'S HOLDINGS OF SOL, THE NATIVE ASSET OF THE SOLANA NETWORK. THE PARTNERSHIP SUPPORTS SOLANA COMPANY'S DIGITAL ASSET TREASURY STRATEGY AS IT CONTINUES TO BUILD ITS POSITION IN SOL. OUR COLLABORATION WITH BITGO REINFORCES HSDT'S COMMITMENT TO A.

SOLANA COMPANY (NASDAQ:HSDT) SELECTS BITGO AS CUSTODIAN FOR SOL TREASURY HOLDINGS

NEWTOWN, PA., OCT. 10, 2025 (GLOBE NEWSWIRE) -- SOLANA COMPANY, (NASDAQ:HSDT OR THE COMPANY"), FORMERLY HELIUS MEDICAL TECHNOLOGIES, INC., TODAY ANNOUNCED IT HAS ENTERED INTO AGREEMENTS WITH COINBASE, BITGO AND ANCHORAGE DIGITAL TO SERVE AS CUSTODIANS AS IT CONTINUES AMASSING SOL, THE NATIVE ASSET OF THE SOLANA NETWORK, AS PART OF ITS DIGITAL ASSETS TREASURY STRATEGY.

PREEMINENT SOL TREASURY VEHICLE, SOLANA COMPANY (NASDAQ:HSDT), ADDS COINBASE, BITGO, AND ANCHORAGE DIGITAL AS CUSTODIANS

HSDT SOLANA COMPANY'S MISSION IS TO MAXIMIZE SOL PER SHARE ON ONE OF THE MOST COMMERCIALLY VIABLE BLOCKCHAINS FOR CONSUMER APPLICATIONS WHILE DELIVERING CONSISTENT ON-CHAIN YIELD FOR INVESTORS

PREEMINENT SOL TREASURY COMPANY HELIUS (NASDAQ:HSDT) ANNOUNCES CORPORATE NAME CHANGE TO SOLANA COMPANY AND LETTER OF INTENT WITH SOLANA FOUNDATION

SEEKING AN INDICATION FOR GAIT AND BALANCE DEFICIT IN PATIENTS WITH CHRONIC SYMPTOMS OF STROKE UNDER ITS BREAKTHROUGH DEVICE DESIGNATION SEEKING AN INDICATION FOR GAIT AND BALANCE DEFICIT IN PATIENTS WITH CHRONIC SYMPTOMS OF STROKE UNDER ITS BREAKTHROUGH DEVICE DESIGNATION

HELIUS ANNOUNCES FDA 510(K) SUBMISSION FOR PONS DEVICE LABEL EXPANSION IN STROKE

NEWTOWN, PA., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (THE "COMPANY" OR "HSDT"), TODAY ANNOUNCED ITS FIRST ACQUISITION OF SOLANA (SOL) TOKENS AS PART OF ITS DIGITAL ASSET TREASURY STRATEGY UNDER WHICH THE PRINCIPAL HOLDING WILL BE SOL, THE NATIVE DIGITAL ASSET OF THE SOLANA BLOCKCHAIN. THE COMPANY NOW HOLDS OVER 760,190 SOL, WITH AN AVERAGE COST BASIS OF $231. THE COMPANY ALSO HOLDS IN EXCESS OF $335 MILLION OF CASH, WHICH IT INTENDS TO USE TO FURTHER THE DIGITAL ASSET TREASURY STRATEGY.

HELIUS (NASDAQ:HSDT) BEGINS PURCHASES OF SOL, THE NATIVE ASSET OF SOLANA BLOCKCHAIN

PREEMINENT SOL-BACKED TREASURY VEHICLE - WITH POTENTIAL TO RAISE OVER $1.25 BILLION AGGREGATE GROSS PROCEEDS - UNLOCKS CAPITAL MARKETS TO ACCELERATESOLANA'S GROWTH THE FINANCING DREW PARTICIPATION FROM LEADING INVESTORS ACROSS TRADITIONAL FINANCE AND CRYPTO, INCLUDING BIG BRAIN HOLDINGS, AVENIR, SINOHOPE, FALCONX, ARRINGTON CAPITAL, ANIMOCA BRANDS, ASPEN DIGITAL, BORDERLESS, LASER DIGITAL, HASHKEY CAPITAL, AND REPUBLIC DIGITAL NEWTOWN, PA. , SEPT. 18, 2025 /PRNEWSWIRE/ -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) ("HELIUS" OR THE "COMPANY") TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT OFFERING (THE "OFFERING") OF COMMON STOCK AND STAPLED WARRANTS TO PURCHASE COMMON STOCK (AND/OR PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN LIEU THEREOF) AT A PURCHASE PRICE OF $6.881 AND STAPLED WARRANTS TO PURCHASE SHARES OF COMMON STOCK WITH AN EXERCISE PRICE EQUAL TO $10.134 PER STAPLED WARRANT.

HELIUS (NASDAQ:HSDT), IN PARTNERSHIP WITH PANTERA CAPITAL AND SUMMER CAPITAL CLOSES OVER $500 MILLION PRIVATE PLACEMENT TO LAUNCH SOL TREASURY COMPANY

NEWTOWN, PA., JULY 21, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS, TODAY ANNOUNCED POSITIVE OUTCOME FROM THE PONS (PORTABLE NEUROMODULATION STIMULATOR) STROKE REGISTRATIONAL PROGRAM (SRP) SUPPORTING A PLANNED FDA SUBMISSION SEEKING AN INDICATION FOR GAIT AND BALANCE DEFICIT IN PATIENTS WITH CHRONIC SYMPTOMS OF STROKE UNDER THE CURRENT BREAKTHROUGH DEVICE DESIGNATION.

HELIUS ANNOUNCES POSITIVE OUTCOME OF THE PORTABLE NEUROMODULATION STIMULATOR PONS STROKE REGISTRATIONAL PROGRAM AND UPCOMING SUBMISSION TO FDA UNDER BREAKTHROUGH DESIGNATION

NEWTOWN, PA., JULY 09, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS,TODAY ANNOUNCED THAT ON JULY 7, 2025, HELIUS RECEIVED FORMAL NOTICE FROM THE NASDAQ HEARINGS PANEL OF THE NASDAQ STOCK MARKET LLC (THE PANEL) INDICATING THAT HELIUS HAS EVIDENCED COMPLIANCE WITH THE EQUITY REQUIREMENT IN LISTING RULE 5550(B)(1) (THE EQUITY RULE) FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET.

HELIUS MEDICAL TECHNOLOGIES, INC. COMPLIANT WITH NASDAQ'S CONTINUED LISTING REQUIREMENTS

NEWTOWN, PA., JUNE 27, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ:HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS, ANNOUNCED TODAY A 1-FOR-50 REVERSE SPLIT OF ITS CLASS A COMMON STOCK, PAR VALUE $0.001 (COMMON STOCK), EFFECTIVE AT 5:00 PM EASTERN TIME ON JUNE 30, 2025. BEGINNING ON JULY 1, 2025, THE COMPANY'S COMMON STOCK WILL TRADE ON THE NASDAQ CAPITAL MARKET ON A SPLIT ADJUSTED BASIS.

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT

- CIGNAHEALTH BECOMES FIFTH MAJOR PAYER TO AUTHORIZE CLAIM FOR PONS DEVICE AT OUT-OF-NETWORK ADJUSTED NEGOTIATED LIST PRICE OF $19,161- -THIS FOLLOWS ANOTHER RECENT AUTHORIZATION BY ANTHEM MULTIPLAN FOR PONS DEVICE AT OUT-OF-NETWORK NEGOTIATED PRICE OF $19,160- NEWTOWN, PA., JUNE 16, 2025 (GLOBE NEWSWIRE) -- HELIUS MEDICAL TECHNOLOGIES, INC. (NASDAQ: HSDT) (HELIUS OR THE COMPANY), A NEUROTECH COMPANY FOCUSED ON DELIVERING A NOVEL THERAPEUTIC NEUROMODULATION APPROACH FOR BALANCE AND GAIT DEFICITS,TODAY ANNOUNCED AN ADDITIONAL AUTHORIZED CLAIM FOR PAYMENT FOR THE PONS DEVICE FROM CIGNAHEALTH.

Helius Medical Technologies, Inc.

HSDT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Helius Medical Technologies, Inc.

HSDT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HSDT